文献速递炎症性肠病

乌司奴单抗诱导治疗后克罗恩病患者症状的演变

Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-06-28

分析乌司奴单抗克罗恩病试验中症状改善的动态变化。患者接受静脉诱导(乌司奴单抗约6 mg/kg,n=458;安慰剂,n=457),评估前14天症状及至第44周临床结局。乌司奴单抗输注后第1天排便频率即显著优于安慰剂,至第10天所有患者报告症状均显著改善。

要点

  • 乌司奴单抗输注后第1天排便频率改善即显著优于安慰剂(P < .05)。
  • 无生物制剂失败史者累积临床缓解率从第3周23.0%升至第16周55.5%。
  • 有生物制剂失败史者累积临床缓解率从第3周12.9%升至第16周24.1%。

核心结论

  • 乌司奴单抗诱导治疗在输注后第1天即提供症状缓解。
  • 输注及皮下90 mg注射后,临床结局持续改善至第16周并延续至第44周。
  • 无论第8周临床状态或乌司奴单抗药代动力学如何,患者均应在第8周接受额外治疗。

研究设计与样本

  • 分析乌司奴单抗克罗恩病试验(NCT01369329、NCT01369342、NCT01369355)中乌司奴单抗反应动态。
  • 克罗恩病患者接受静脉诱导:乌司奴单抗约6 mg/kg(n=458)或安慰剂(n=457)。
  • 第8周乌司奴单抗应答者接受皮下乌司奴单抗90 mg作为首次维持剂量,无应答者接受延长诱导剂量。

主要发现

  • 乌司奴单抗输注后第1天排便频率改善显著大于安慰剂(P < .05),至第10天所有患者报告症状均显著改善。
  • 无生物制剂失败或不耐受史患者累积临床缓解率从第3周23.0%升至第16周55.5%(第8周皮下给药后)。
  • 有生物制剂失败或不耐受史患者累积临床缓解率从第3周12.9%升至第16周24.1%。
  • CD活动指数评分自基线变化及第8周乌司奴单抗药代动力学均与第16周应答无关。
  • 所有接受皮下乌司奴单抗90 mg每8周一次的患者中,至第44周高达66.7%处于临床应答。

关键数值与推荐

  • 排便频率改善:乌司奴单抗组第1天显著大于安慰剂组(P < .05)。
  • 无生物制剂失败史:累积临床缓解率第3周23.0% vs 第16周55.5%。
  • 有生物制剂失败史:累积临床缓解率第3周12.9% vs 第16周24.1%。
  • 皮下乌司奴单抗90 mg每8周一次患者至第44周临床应答率高达66.7%。

临床怎么用

  • 乌司奴单抗诱导治疗可在输注后第1天即开始症状缓解。
  • 无论第8周临床状态或乌司奴单抗药代动力学如何,患者应在第8周接受额外治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ustekinumab is an effective treatment of Crohn's disease (CD). Of interest to patients is knowing how soon symptoms may improve. We analyzed ustekinumab response dynamics from the ustekinumab CD trials. METHODS: Patients with CD received intravenous induction with ustekinumab ∼6 mg/kg (n = 458) or placebo (n = 457). Week 8 ustekinumab responders received subcutaneous ustekinumab 90 mg as the first maintenance dose or as an extended induction dose for nonresponders. Patient-reported symptom changes (stool frequency, abdominal pain, general well-being) within the first 14 days and clinical outcomes through week 44 were evaluated using the CD Activity Index. RESULTS: After ustekinumab infusion, stool frequency improvement was significantly (P < .05) greater than placebo on day 1 and for all patient-reported symptoms by day 10. In patients with no history of biologic failure or intolerance, cumulative clinical remission rates increased from 23.0% at week 3 to 55.5% at week 16 after the subcutaneous dose at week 8. Corresponding cumulative rates for patients with a history of biologic failure or intolerance increased from 12.9% to 24.1%. Neither change from baseline in CD Activity Index score nor week 8 ustekinumab pharmacokinetics were associated with week 16 response. Among all patients who received subcutaneous ustekinumab 90 mg q8w, up to 66.7% were in clinical response at week 44. CONCLUSIONS: Ustekinumab induction provided symptom relief by day 1 post-infusion. Following ustekinumab infusion and a subcutaneous 90 mg injection, clinical outcomes continued to increase through week 16 and up to week 44. Regardless of week 8 clinical status or ustekinumab pharmacokinetics, patients should receive additional treatment at week 8. CLINICALTRIALS: gov numbers, NCT01369329, NCT01369342, and NCT01369355.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Colombel JF, Sands BE, Gasink C, et al. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2023. PMID: 37391056. doi:10.1016/j.cgh.2023.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。